ProQR Therapeutics NV (PRQR) News & EventsPRQRNews & EventsProQR Therapeutics NV

Company Does Not Sell 3.03M Ordinary Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.03M ordiary shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

ProQR Therapeutics Prices 27.6M Share Offering at $1.81

ProQR Therapeutics (PRQR) announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares at an offering price of $1.81 per share (the "Offering Price"), for total gross proceeds of approximately $50M, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. Concurrently with the Offering, ProQR has entered into a share purchase agreement with Eli Lilly and Company (LLY) in a separately negotiated transaction pursuant to which ProQR agreed to offer and sell, and Lilly agreed to purchase, 5,100,780 ordinary shares, to permit Lilly to maintain its pro rata beneficial ownership, at the Offering Price, for total gross proceeds of approximately $9.2M, subject to the consummation of the Offering and the satisfaction of other customary closing conditions. The sale of ordinary shares to Lilly in the concurrent private placement will not be registered as part of the Offering. The closing of the Offering is not contingent upon the closing of the concurrent private placement. The ordinary shares purchased in the concurrent private placement will not be subject to any underwriting discounts or commissions. BofA Securities, Evercore ISI and Cantor are acting as joint lead bookrunning managers for the Offering, and Oppenheimer & Co. is acting as a bookrunning manager for the Offering. The Offering and concurrent private placement are expected to close on or about June 26.

ProQR Therapeutics Reports Positive Phase 1 Data for AX-0810

ProQR Therapeutics announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the company's first investigational Axiomer RNA editing oligonucleotide, or EON, in healthy volunteers. Axiomer is the company's proprietary RNA editing technology platform. AX-0810 is an Axiomer RNA EON which aims to reduce toxic bile acid accumulation in the liver, the underlying driver of cholestatic liver diseases including biliary atresia, and has the potential to be disease modifying. Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohorts. AX-0810 demonstrated up to 8-fold change in total bile acids in serum, exceeding the 2-fold threshold identified by the company as a meaningful indicator of NTCP modulation, along with concordant readouts of bile acid profile and TUDCA markers. Favorable safety and tolerability profile has been observed with AX-0810 to date, with no serious adverse events or pruritus reported; pharmacokinetic findings to date support sustained target engagement, including a half-life of eight weeks. The NTCP biomarker findings support the advancement of next-generation candidate AX-0811 and future clinical studies in biliary atresia. ProQR expects to submit a Clinical Trial Application in mid-2026 for AX-0811 and anticipates initial human clinical data in healthy volunteers by year-end 2026. The company has selected biliary atresia as the initial indication for Phase 2 development of AX-0810 or AX-0811. The company expects to report initial clinical data from the trial in the first half of 2027.